| |
In silico trials are emerging as an alternative to randomized controlled trials for rare diseases, particularly where no standard of care exists, or placebo is unethical. Download our whitepaper to learn more about this transformative approach. 
|
|
Today’s Big NewsNov 11, 2024 |
| By Nick Paul Taylor The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol Myers Squibb. |
|
|
|
By Gabrielle Masson Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine program. |
By James Waldron Rapt Therapeutics had been holding out hopes that its immunology drug zelnecirnon still had a future despite facing a clinical hold, but the latest feedback from the FDA has persuaded the biotech to give up on the program. |
Sponsored by IO Biotech Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform the cancer treatment landscape. |
|
Experience how our CMC and regulatory capabilities help achieve seamless, timely launches. Give your molecule the best chance of success. Start today. 
|
|
By Zoey Becker The company opted not to renew its membership for 2025 following an annual review of its trade group associations, a spokesperson said. |
By Nick Paul Taylor Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing Evotec’s share price fall around 60% this year, Triton Partners has raised its stake in the drug discovery shop and is reportedly considering a buyout bid. |
By James Waldron Ideaya has decided to go ahead with its bispecific ADC plans, exercising its option to pick up a preclinical asset from China’s Biocytogen that Ideaya hopes can turbocharge the effect of its DNA damage repair molecules. |
By Conor Hale During quarterly earnings calls this week across the medtech industry, a recurring question has been on investors’ minds. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we take a closer look at this year’s biotech graveyard, which tracks biotechs that have closed or are winding down. |
|
|---|
|
|
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
